GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.45
Bid: 40.05
Ask: 40.50
Change: 3.30 (8.88%)
Spread: 0.45 (1.124%)
Open: 37.95
High: 40.80
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

John Clarke to Chair Futura

1 Nov 2011 07:00

RNS Number : 2026R
Futura Medical PLC
01 November 2011
 



For immediate release

1 November 2011

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Appointment of Non-Executive Chairman

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is delighted to announce the appointment of John Clarke, the highly experienced GlaxoSmithKline ("GSK") executive, as Non-Executive Chairman.

Mr Clarke has extensive experience of the healthcare sector, having worked at GSK for more than 35 years. In 2006 he was appointed President of GSK Consumer Healthcare, a position from which he recently stepped down. Under Mr Clarke's leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. It achieved 60% sales growth between 2006 and 2010, when it recorded a turnover of £5 billion.

Mr Clarke's appointment at Futura will be effective on 1 February 2012.

Mr Clarke will replace Dr William Potter, who will step down from the Board on 1 February 2012 but continue to play a key role as Futura's Chief Scientific Officer. David Davies, Futura's Product Development Director, becomes Chief Development Director, reflecting the Company's increasing emphasis on its product pipeline.

John Clarke, Futura's Chairman Designate, commented: "I am delighted to be taking on the Chairmanship of Futura. I am particularly impressed by the level of innovation at Futura, by the commercial potential of its late stage products and by the breadth of its product pipeline. I look forward to assisting the Company in achieving its true potential."

James Barder, Futura's Chief Executive, said: "John Clarke is recognised as an outstanding leader in the consumer healthcare industry and we are therefore delighted that he has decided to join Futura at this exciting stage in our development. I would like to give my profound thanks to Bill Potter for his tenure as Chairman, and am delighted that he will be remaining with the Company as Chief Scientific Officer."

 

 

Additional information:

 

John Milne Clarke, age 62 years, holds no shares in Futura. He was President of GlaxoSmithKline Worldwide Consumer Healthcare. He is a member of GlaxoSmithKline plc Corporate Executive Team and a director of the US-based Consumer Healthcare Products Association.

 

There are no further disclosures to be made in relation to Mr Clarke under Schedule 2(g) and (i) of the AIM rules.

 

 

 

For any further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact:

Buchanan

Mark Court / Jessica Fontaine

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDFLFXFBFFFBK
Date   Source Headline
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares
10th Sep 20157:00 amRNSGrant of Options
9th Sep 20157:00 amRNSInterim Results
19th Aug 20153:15 pmRNSNotification of Major Interest in Shares
19th Aug 20157:00 amRNSNotice of Interim Results
16th Jul 20154:23 pmRNSNotification of Major Interest in Shares
14th Jul 20157:00 amRNSHeadline Results from Pain Relief Study
13th Jul 20157:00 amRNSNotice of Pain Relief Portfolio Study Results
25th Jun 20157:00 amRNSCommencement of MED2002 Clinical Trial
17th Jun 20155:45 pmRNSResult of AGM
17th Jun 20157:00 amRNSAGM Statement
3rd Jun 20155:20 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20157:00 amRNSPain Relief Portfolio: Study Update
11th May 20157:00 amRNSBlock Listing Update
11th May 20157:00 amRNSBlue Diamond® Retail Roll-out
24th Apr 20153:00 pmRNSNotice of AGM
31st Mar 20155:05 pmRNSNotification of Major Interest in Shares
25th Mar 20157:00 amRNSPreliminary Results
18th Mar 20157:00 amRNSPain Relief Portfolio Study Commences
16th Mar 20155:48 pmRNSAIM Disclosure
3rd Mar 20154:52 pmRNSNotification of Major Interest in Shares
5th Feb 20157:00 amRNSUS Patent Extension for MED2002
2nd Feb 20151:18 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
28th Jan 20151:10 pmRNSNotification of Major Interest in Shares
23rd Jan 201510:14 amRNSNotification of Major Interest in Shares
22nd Jan 20152:33 pmRNSDirector Shareholding
15th Jan 201512:32 pmRNSNotification of Major Interest in Shares
15th Jan 201512:14 pmRNSDirector's Dealings
15th Jan 20157:00 amRNSNotice of Preliminary Results
5th Jan 20157:00 amRNSRemuneration of Non-Executive Directors
15th Dec 20147:00 amRNSAppointment of CRO for MED2002 Clinical Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.